Table 3. Evolution of second line treatment for recurrent cervical cancer.

	First line therapy			Second line therapy
	GOG-204	GOG-240	Keynote-826	EMPOWER	Innova TV 301
Treatment	CDDP+Paclitaxel	Doublet+ Bevacizumab	ChemoRx+Pembrolizumab with or without Bevacizumab	Cemiplimab	Tisotumab Vedotin
Median OS	12.0 mo	17.0 mo, HR 0.71	24.4 mo, HR 0.64	12.0 mo, HR 0.69	11.5 mo, HR 0.70
ORR	29.1%	48.0%	68.1% in PD-L1+≥1%	18.0% in PD-L1+≥1%	17.8%
Citation	Monk BJ, et al. J Clin Oncol 2009;27:4649-55.	Tewari KS, et al. N Engl J Med 2014;370:734-43.	Colombo N, et al. N Engl J Med 2021;385:1856-67.	Tewari KS, et al. N Engl J Med 2022;386:544-55.	Vergote I, et al. ESMO 2023 LBA#9, NCT04697628.

CDDP, cisplatin; HR, hazard ratio; ORR, overall response rate; OS, overall survival; PD-L1, programmed death-ligand 1.